Monoclonal antibody therapy of leukaemias and lymphomas

Bibliography

• KOHLER G, MILSTEIN C: Continuouscultures of fitsed cells secreting antibody of predefined specificity. Nature (1975) 256:495–497.
   PubMed Web of Science ®Google Scholar
• REFF ME, GARNER K, CHAMBERS KSet al.: Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood (1994) 83:435–445.
   Google Scholar
• RIECHMANN L, CLARK M, WALDMANN H, WINTER G: Reshaping human antibodies for therapy. Nature (1988) 332:323–327.
   PubMed Web of Science ®Google Scholar
• CHINN PC, LEONARD JE, ROSENBERG J, HANNA N, ANDERSON DR: Preclinical evaluation of 90Y-labeled anti-CD20 monoclonal antibody for treatment of non-Hodgkin's lymphoma. Int. J. Oncol. (1999) 15:1017–1025.
   PubMed Web of Science ®Google Scholar
• SIEVERS EL, LARSON RA, STADTMAUER EA et al.: Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J. Clin. Oncol (2001) 19:3244–3254.
   PubMed Web of Science ®Google Scholar
• CARTRON G, WATIER H, GOLAY J, SOLAL-CELIGNY P: From the bench to the bedside: ways to improve rituximab efficacy. Blood (2004) 104:2635–2642.
   PubMed Web of Science ®Google Scholar
• GOLAY JT, CLARK EA, BEVERLEY PC: The CD20 (Bp35) antigen is involved in activation of B cells from the GO to the G1 phase of the cell cycle. J. Immunol (1985) 135:3795–3801.
   PubMed Web of Science ®Google Scholar
• GOLAY J, LAZZARI M, FACCHINETTI Vet al.: CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia:further regulation by CD55 and CD59. Blood (2001) 98:3383–3389.
   Google Scholar
• GOLAY J, ZAFFARONI L, VACCARI Tet al.: Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood (2000) 95:3900–3908.
   Google Scholar
• TREON SP, MITSIADES C, MITSIADES N et al.: Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies. J. Immunol (2001) 24:263–271.
   Google Scholar
• WINKLER U, JENSEN M, MANZKE 0 et al.: Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (Rituximab, IDEC-C2B8). Blood (1999) 94:2217–2224.
   Google Scholar
• CARTRON G, DACHEUS L, SALLES G et al.: Therapeutic activity of humanized anti-CD20 monoclonal antigody and polymorphism in IgG Fc receptor FeYRIIIa gene. Blood (2002) 99:754–758.
   PubMed Web of Science ®Google Scholar
• WENG WK, LEVY R: Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J. Clin. Oncol (2003) 21:3940–3947.
   PubMed Web of Science ®Google Scholar
• WENG WK, LEVY R: Rituximab-inducedantibody-dependent cellular cytotoxicity (ADCC) in follicular non-Hodgkin's lymphoma [abstract]. Blood (2002) 100:1368a.
   Google Scholar
• SELENKO N, MAJDIC 0, JAGER U et al.: Cross-priming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive antibodies?" Clin. Immunol (2002) 22:124–130.
   Google Scholar
• RAFIQ K, BERGTOLD A, CLYNES R: Immune complex-mediated antigen presentation induces tumor immunity. Clin. Invest. (2002) 110:71–79.
   Google Scholar
• KALERGIS AM, RAVETCH JV: Inducing tumor immunity through the selective engagement of activating FcY receptors on denclritic cells. J. Exp. Med. (2002) 195:1653–1659.
   PubMed Web of Science ®Google Scholar
• WITZIG TE, GORDON LI, CABANILLAS F: Randomized controlled trial of yttrium-90 labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma." Clin. Oncol. (2002) 20:2453–2463.
   PubMed Web of Science ®Google Scholar
• WITZIG TE, FLINN IW, GORDON LI, EMMANOUILIDES C: Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. Clin. Oncol. (2002) 20:3262–3269.
   Web of Science ®Google Scholar
• DILLMAN RO: Radiolabeled anti-C20 monoclonal antibodies for the treatment of B-cell lymphoma. J. Clin. Oncol (2002) 20:3557.
   Google Scholar
• WITZIG TE, GORDON L, GASTON I, EMMANOUILIDES E: 90Y ibritumomab tiuxetan (Zevalin) radioimmunotherapy of follicular NHL: results by follicular subtype [abstract]. Proc. Am. Soc. Clin. Oncol (2002) 21:1063a.
   Google Scholar
• VOSE JM, WAHL RL, SALEH M: Multicenter Phase II study of iodine-131 tostumomab for chemotherapy-relapsed/ refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. 1 Clin. Oncol (2000) 18:1316–1323.
   PubMed Web of Science ®Google Scholar
• DAVIS T, KAMINSKI M, LEONARD J et al.: Results of a randomized study of Bexxar (tositumomab and Iodine-131 tositumomab) versus unlabelled tostitumomab in patients with relapsed or refractory low-grade or transformed non-Hodgkin's lymphoma [abstract]. Blood (2001) 98:843a.
   Web of Science ®Google Scholar
• KAMINSKI MS, ZELENETZ AD, PRESS OW: Pivotal study of iodine 1131 tositumomab for chemotherapyrefractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J. Clin. Oncol (2001) 19:3918–3928.
   PubMed Web of Science ®Google Scholar
• KAMINSKI MS, TUCK M, REGAN D, KISON P, WAHL RL: High response rates and durable remissions in patients with previously untreated, advanced-stage, follicular lymphoma treated with tositumomab and iodine 1-131 tositumomab (Bexxare) [abstract]. Blood (2002) 100:356a.
   PubMedGoogle Scholar
• KAMINSKI M, TUCK M, ESTES J et al.: 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl. J. Med. (2005) 352:441–449.
   PubMed Web of Science ®Google Scholar
• KAMINSKI MS, ESTES J, ZASADNY KR et al.: Radioimmunotherapy with iodine loll tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood (2000) 96:1259–1266.
   PubMed Web of Science ®Google Scholar
• GROVES FD, LINET MS, TRAVIS LB: Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995.1 Natl. Cancer Inst. (2000) 92:1240–1251.
   PubMed Web of Science ®Google Scholar
• THE NON-HODGKIN'S LYMPHOMA CLASSIFICATION PROJECT: A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. Blood (1997) 89:3909–3918.
   Google Scholar
• KORSMEYER S: Bc1-2 initiates a new category of oncogenes: regulators of cell death. Blood (1992) 80:879–886.
   PubMed Web of Science ®Google Scholar
• PORTLOCK CS, ROSENBERG SA: No initial therapy for stage II and IV non-Hodgkin's lymphoma of favorable histologic types. Ann. Intern. Med. (1979) 90:10.
   PubMed Web of Science ®Google Scholar
• STRAUS DJ, GAYNOR JJ, LEIBERMAN PH et al.: Non-Hodgkin's lymphomas: characteristics of long-term survivors following conservative treatment. Am. J. Med. (1986) 82:247.
   Web of Science ®Google Scholar
• MALONEY DG, GRILLO-LOPEZ AJ, BODKIN DJ: IDEC-C2B8: results of a Phase I multi-dose trial in patients with relapsed non-Hodgkin's lymphoma. Clin. Oncol (1997) 15:3266.
   Web of Science ®Google Scholar
• MCLAUGHLIN P, GRILLO-LOPEZ AJ, LINK BK: Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. Clin. Oncol (1998) 16:2825.
   Web of Science ®Google Scholar
• COLOMBAT P, SALLES G, BROUSSE N et al.: Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood (2001) 97:101–106.
   PubMed Web of Science ®Google Scholar
• PIRO LD, WHITE AJ, GRILLO-LOPEZ AJ et al.: Extended rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann. Oncol (1999) 10:655–661.
   PubMed Web of Science ®Google Scholar
• HAINS WORTH JD, LITCHY S, BURRIS HA 3RD et al.: Rituximab as first line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma. Clin. Oncol (2002) 20:4261–4267.
   Google Scholar
• HAINS WORTH JD, BURRIS HA 3RD, MORRISSEY LH et al.: Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood (2000) 95:3052–3056.
   Google Scholar
• GORDAN LN, GROW WB, PUSATERI A et al.: Phase II trial of individualized rituximab dosing for patients with CD20-positive lymphoproliferative disorders. 1 Clin. Oncol (2005) 23:1096–1102.
   Google Scholar
• CZUCZMAN M, GRILLO-LOPEZ AJ, MCLAUGHLIN P, WHITE CA: Clearing of cells bearing the bc1-2 [t(14; 18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy. Ann. Oncol (2001) 12:109–114.
   PubMed Web of Science ®Google Scholar
• CZUCZMAN M, WEAVER R, ALKUZWENY B, BERLFEIN J, GRILLO-LOPEZ AJ: Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. Clin. Oncol. (2004) 22:4711–4716.
   Web of Science ®Google Scholar
• CZUCZMAN M, KORYZNA A, MOHR A et al.: Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma. Clin. Oncol. (2005) 23:694–704.
   Web of Science ®Google Scholar
• FORSTPOINTNER R, DREYLING M, REPP R et al.: The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood (2004) 104:3064–3071.
   PubMed Web of Science ®Google Scholar
• HOCHSTER HS, WELLER E, RYAN T et al.: Results of E1496: a Phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL) [abstract]. 1 Clin. Oncol (2004) 22:558s.
   Google Scholar
• MARCUS R, IMRIE K, BELCH A et al.:CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma [abstract]. Blood (2005) 105:1417–1423.
   PubMed Web of Science ®Google Scholar
• LEONARD JP, COLEMAN M, KETAS JC et al.: Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma [abstract]. 1 Clin. Oncol. (2003) 21:3051–3059.
   Google Scholar
• CZUCZMAN M, WITZIG TE, VOSE JM et al.: Results of a Phase I/II multicenter trial of galiximab (IDEC-114, anti-CD80 antibody) therapy for relapsed or refractory follicular lymphoma [abstract]. Blood (2003) 102:647a.
   Web of Science ®Google Scholar
• LINK BK, WANG H, BYRD JC et al.: Phase I study of Hul D10 monoclonal antibody in patients with B-cell lymphoma [abstract]. J. Clin. Oncol. (2001) 20:284a.
   Google Scholar
• DAVIS TA, KAMINSKI MS, LEONARD JP et al.: The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin. Cancer Res. (2004) 10:7792–7798.
   PubMed Web of Science ®Google Scholar
• PRESS OW, UNGER JM, BRAZIEL RM: A Phase II trial of CHOP chemotherapy followed by tositumomab/iodine 1131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S9911. Blood (2003) 102: 1606-1612.
   Google Scholar
• LEONARD JP, COLEMAN M, KOSTAKOGLU Let al.: Durable remissions from fludarabine followed by the iodine 1–131 tositumomab Bexxar therapeutic regimen for patients with previously untreated follicular non-Hodgkin's lymphoma (NHL) [abstract]. J. Clin. Oncol (2004) 22:6518.
   Google Scholar
• SHIPLEY DL, SPIGEL DR, CARRELL DL et al.: Phase II trial of rituximab and short duration chemotherapy followed by "Y-ibritumomab tiuxetan as first-line treatment for patients with follicular lymphoma: A Minnie Pearl Cancer Research Network Phase II trial [abstract]. J. Clin. Oncol (2004) 22:6519.
   Web of Science ®Google Scholar
• LINK B, KAMINSKI MS, COLEMAN M, LEONARD JP: Phase II study of CVP followed by tositumomab and iodine 1131 tositumomab (Bexxar therapeutic regimen) in patients with untreated follicular non-Hodgkin's lymphoma (NHL) [abstract]. 1 Clin. Oncol (2004) 22:6520.
   Web of Science ®Google Scholar
• HARRIS NL, JAFFE ES, DIEBOLD J: The World Health Organization classification of hematological malignancies: report of the Clinical Advisory Committee meeting. November 1997. The United States and Canadian Academy of Pathology, Inc., Airlie House, Virginia, USA. Clin. Oncol (2000) 13:193–207.
   Google Scholar
• WORLD HEALTH ORGANIZATION: Classification Of Tumours. Pathology And Genetics Of Tumours Of Haematopoietic And Lymphoid Tissues. Jaffe ES, Harris NL, Stein H, Vardiman JW (Eds), IARC Press, Lyon, France (2001).
   Google Scholar
• MOLLEJO M, MENARGUEZ J, LLORET E: Splenic marginal zone lymphoma: a distinctive type of low-grade B-cell lymphoma. A clinicoppathological study of 13 cases. Am. J. Surg Pathol (1995) 19:1146–1157.
   PubMed Web of Science ®Google Scholar
• JENNINGS CD, FOON KA: Recent advances in flow cytometry: application to the diagnosis of hematologic malignancy. Blood (1997) 90:2863.
   PubMed Web of Science ®Google Scholar
• WOTHERSPOON AC, PAN LX, DISS TC, ISAACSON PG: Cytogenetic study of B-cell lymphoma of mucosa-associated lymphoid tissue. Cancer Genet. Cytogenet. (1992) 8:35.
   Google Scholar
• OTT G, KATZENBERG T, GREINER A:The t(11;18)(q21;q21) chromosome translocation is a frequent and specific aberration in low-grade but not high-grade malignant non-Hodgkin's lymphomas of the mucosa-associated lymphoid tissue (MALT) type. Cancer Res. (1997) 57:3944.
   PubMed Web of Science ®Google Scholar
• CONCONI A, MARTINELLI G, THIEBLEMONT C: Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood (2003) 102:2741–2745.
   PubMed Web of Science ®Google Scholar
• MARTINELLI G, LASZLO D, FERRERI AJ et al: Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. 1 Clin. Oncol (2005) 23:1979–1983.
   PubMed Web of Science ®Google Scholar
• THE NON-HODGKIN'S LYMPHOMA CLASSIFICATION PROJECT: The Non-Hodgkin's Lymphoma Pathologic Classification Project: National Cancer Institute Sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a Working Formulation for clinical usage. Cancer (1982) 49:2112.
   Google Scholar
• HARRIS NL, JAFFE ES, DIEBOLD J: World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.1 Clin. Oncol (1999) 17:3835–3849.
   PubMed Web of Science ®Google Scholar
• SWERDLOW SH, HABESHAW JA, MURRAY LJ et al: Centrocytic lymphoma. A distinct clinicopathologic and immunologic entity. A multiparameter study of 18 cases at diagnosis and relapse. Am. J. PathoL (1983) 113:181.
   Google Scholar
• LARDELLI P, BOOKMAN MA, SUNDEEN J, LONGO DL, JAFFE ES: Lymphocytic lymphoma of intermediate differentiation. Morphologic and immunophenotypic spectrum and clinical correlations. Am J. Surg. PathoL (1990) 14:752.
   Google Scholar
• HIDDEMANN W, UNTERHALT M, HERRMANN R: Mantle-cell lymphoma have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German low-grade lymphoma study group. 1 Clin. Oncol (1998) 16:1922.
   Google Scholar
• VELDERS GA, KLUIN-NELEMANS JC, DE BOER CJ: Mantle-cell lymphoma: a population-based clinical study. J. Clin. Oncol (1996) 14:1269.
   PubMed Web of Science ®Google Scholar
• ARATOFF LH, CONNORS JM, KLASA RJ, HORSMAN DE, GASCOYNE RD: Mantle cell lymphoma: a clinicopathologic study of 80 cases. Blood (1997) 89:2067.
   PubMed Web of Science ®Google Scholar
• MAJLIS k PUGH WC, RODRIGUEZ MA, BENEDICT WF, CABANILLAS F: Mantle cell lymphoma: correlation of clinical outcome and biologic features with three histologic variants. Clin. Oncol (1997) 15:1664.
   Web of Science ®Google Scholar
• PRESS OW, GROGAN TM, FISHER RI: Evaluation and management of mantle cell lymphoma. Adv. Leuk. Lymphoma (1996) 6:3.
   Google Scholar
• MEUSERS P, HENSE J, BRITTINGER G: Mantle cell lymphoma: diagnostic criteria, clinical aspects and therapeutic problems. Leukemia (1997) 11:S60–S64.
   PubMed Web of Science ®Google Scholar
• ZUCCA E, ROGGERO E, PINOTTI G: Patterns of survival in mantle cell lymphoma. Ann. Oncol (1995) 6:257–262.
   PubMed Web of Science ®Google Scholar
• VANDENBERGHE E, DEWOLF-PEETERS C, VAUGHAN HG: Clinical outcome of 65 cases of mantle cell lymphoma initially treated with non-intensive therapy by the British National Lymphoma Investigation Group. Br. J. HaematoL (1997) 99:842–847.
   PubMed Web of Science ®Google Scholar
• MEUSERS P, ENGELHARD M, BARTELS H: Multicentre random therapeutic trial for advanced centrocytic lymphoma: anthracycline does not improve the prognosis. Hematol Oncol. (1989) 7:365–380.
   PubMed Web of Science ®Google Scholar
• GHIELMINI M, HSU SCHMITZ SF, BORKI K: The effect of rituximab on patients with follicular and mantle-cell lymphoma. Ann. Oncol (2000) 11:S123–5126.
   PubMed Web of Science ®Google Scholar
• FORAN JM, ROHATINER AZ, CUNNINGHAM D: European Phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J. Clin. Oncol (2000) 18:317–324.
   PubMed Web of Science ®Google Scholar
• HOWARD OM, GRIBBEN JG, NEUBERG DS, GROSSBARD M: Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: Molecular complete responses are not predictive or pregression-free survival. J. Clin. Oncol. (2002) 20:1288–1294.
   PubMed Web of Science ®Google Scholar
• HIDDEMANN W, DREYLING M, UNTERHALD M: Rituximab plus chemotherapy in collicular and mantle cell lymphoma. Semin. Oncol (2003) 30:16–20.
   PubMed Web of Science ®Google Scholar
• DRACH J, KAUFMANN H, PUESPOEK A et al.: Marked anti-tumor activity of rituximab plus thalidomide in patients with relapsed/resistant mantle cell lymphoma [abstract]. Blood (2002) 100:162a.
   Web of Science ®Google Scholar
• DRACH J, KAUFMANN H, WOEHRER S, CHOTT C: Durable remissions after rituximab plus thalidomide for relapsed/refractory mantle cell lymphoma [abstract]. Proc. Am. Soc. Clin. Oncol (2004) 23:6583a.
   Google Scholar
• KAUFMANN H, RAFIQ K, WOEHRER S et al: Brief report: Antitumor activity of rituximab plus thalidomide in patients with relapsed/ refractory mantle cell lymphoma. Blood (2004) 104:2269–2271.
   PubMed Web of Science ®Google Scholar
• LEFRÉ F, DELMER A, SUZAN F: Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia (2002) 16:587–593.
   PubMed Web of Science ®Google Scholar
• KHOURI IF, RAMAGUERA J, KANTARJIAN H: Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. J. Clin. Oncol (1998) 16:3803–3809.
   PubMed Web of Science ®Google Scholar
• ROMAGUERA JE, DANG NH, HAGEMEISTER FB: Preliminary report of rituximab with intensive chemotherapy for untreated aggressive mantle-cell lymphoma [abstract]. Blood (2000) 96:733a.
   Web of Science ®Google Scholar
• ROMAGUERA JE, FAYAD L, RODRIGUEZ MA et al.: Rituximab plus hypercvad (R-HCVAD) alternating with rituximab plus high-dose methotrexate-cytarabine (R-M/A) in untreated mantle cell lymphoma (MCL): prolonged follow-up confirms high rates of failure-free survival (FFS) and overall survival (OS) [abstract]. Blood (2004) 104:40a.
   PubMed Web of Science ®Google Scholar
• DREYLING M, LENZ G, HOSTER E et al.: Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood (2005) 105:2677–2684.
   PubMed Web of Science ®Google Scholar
• OKI Y, PRO B, DELPASSAND E et al: A Phase II study of yitrium 90 (90Y) ibritumomab tiuxetan (Zevaline) for treatment of patients with relapsed and refractory mantle cell lymphoma (MCL) [abstract]. Blood (2004) 104:720a.
   Web of Science ®Google Scholar
• DAVIS TA, WHITE CA, GRILLO-LOPEZ AJ, VELASQUEZ WS, MALONEY LB: Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: results of a Phase II trial of rituximab. J. Clin. Oncol (1999) 17:1851–1857.
   PubMed Web of Science ®Google Scholar
• BEHR TM, GRIESINGER F, RIGGERT Jet al.: High-dose myeloalabive radioimmunotherapy of mantle cell non-Hodgkin lymphoma with the iodine-131-labeled chimeric anti-CD20 antibody C2B8 and autologous stem cell support. Cancer (2002) 94:1363–1372.
   Google Scholar
• GOPAL AK, RAJENDRAN JG, PETERSDORF SH, MALONEY DG: High-dose chemo-radioimmunotherapy with autologous stem cell support for relapsed mantle cell lymphoma. Blood (2002) 99:3158–3162.
   PubMed Web of Science ®Google Scholar
• ARMITAGE J, WEISENBURGER DD: New approach to classifying non-Hodgkin's lymphomas: Clinical features of the major histologic subtypes. J. Clin. Oncol (1998) 16:2780.
   PubMed Web of Science ®Google Scholar
• ALIZADEH AE, EISEN MB, DAVIS E et al.: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature (2000) 403:503–511.
   PubMed Web of Science ®Google Scholar
• HUANG JS, SANGER WG, GREINER TC et al: The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood (2002) 99:2285–2290.
   PubMed Web of Science ®Google Scholar
• GASCOYNE RD, ADOMAT SA, KRAJEWSKI S et al.: Prognostic significance of Bc1-2 protein expression and Bc1-2 gene rearrangement in diffuse aggressive non-Hodgkin's lymphma. Blood (1997) 90:244–251.
   PubMed Web of Science ®Google Scholar
• LOSSOS IJ, ADOMAT SA, JONES CD et at.: Expression of a single gene, BCL-6, strongly predicts survival in patients with diffuse large B-cell lymphoma. Blood (2001) 98:945–951.
   Google Scholar
• SHIPP M, ROSS KN, TAMAYO P: Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat. Med. (2002) 8:68.
   PubMed Web of Science ®Google Scholar
• HANS CP, WEISENBURGER DD, GREINER TC et al.: Confirmation of the molecular classifiction of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood (2004) 103:275–282.
   PubMed Web of Science ®Google Scholar
• DOGGETT R, WOOD GS, HORNING S: The immunologic characterization of 95 nodal and extranodal diffuse large cell lymphomas in 89 patients. Am. J. Pathol (1984) 115:245.
   PubMed Web of Science ®Google Scholar
• STEIN H, LENNERT K, FELLER AC, MASON DY: Immunohistological analysis of human lymphoma: correlation of histological and immunological categories. Adv. Cancer Res. (1984) 42:67.
   PubMed Web of Science ®Google Scholar
• COIFFIER B, HAIOUN C, KETTERER N et al: Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter Phase II study. Blood (1998) 92: 1927-1932.
   Google Scholar
• COIFFIER B, LEPAGE E, BRIERE J: CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse B-cell lymphoma. N Engl. J. Med. (2002) 346:235.
   PubMed Web of Science ®Google Scholar
• MOUNIER N, BRIERE J, GISSELBRECHT C et al.: Rituximab plus CHOP (R-CHOP) overcomes bc1-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood (2003) 101:4279–4284.
   PubMed Web of Science ®Google Scholar
• HABERMANN TM, WELLER EA, MORRISON VA et al.: Phase III trial of rituximab-CHOP (R-CHOP) versus CHOP with a second randomization to maintenance rituximab (MR) or observation in patients 60 years of age and older with diffuse large B-cell lymphoma (DLBCL). Blood (2003) 102:6a.
   Web of Science ®Google Scholar
• HABERMANN TM, WELLER E, MORRISON VA et al: Rituximab-CHOP versus CHOP with or without maintenance rituximab in patients 60 years or age or older with diffuse large B-cell lymphoma (DLBCL): an update. Blood (2004) 104:40a. Expert Op/n. Biol. Ther (2005) 5(9)
   Google Scholar
• PFREUNDSCHUH MG, TROMPER L, MAD et al.: Randomized intergroup trial of first line treatment for patients =60 years with diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with a CHOP like regimen with or without the anti-CD20 antibody rituximab - early stopping after the first interim analysis. Proc. Am. Soc. Clin. Oncol (2004) 22:6500.
   Google Scholar
• WILSON WH, FRANKEL SR, DRBOHLAV N et al.: Phase II study of dose-adjusted EPOCH-rituximab in untreated high risk large B-cell lymphomas [abstract]. Proc. Am. Soc. Clin. Oncol (2001) 20:290a.
   Google Scholar
• KEWALRAMANI T, ZELENETZ A. BERTINO J et al.: Rituximab significantly increases the complete response rate in patients with relapsed or primary refractory DLBCL receiving ICE as second-line therapy (SLT). Blood (2001) 98:346a.
   Google Scholar
• GORDON LI, WITZIG TE, EMMANOUILIDES CE et al.: ibritumomab (Zevalin) in aggressive non-Hodgkin's lymphoma: analysis of response and toxicity [abstract]. Proc. Am. Soc. Clin. Oncol (2002) 21:266a.
   Google Scholar
• MORSCHHAUSER F, HUGLO D, MARTINELLI G et al.: Yttrium-90 ibritumomab tiuxetan (Zevalin) for patients with relapsed/refractory diffuse large B-cell lymphoma not appropriate for autologous stem cell transplantation: results of an open label Phase II trial. Blood (2004) 104:41a.
   Web of Science ®Google Scholar
• PRESS OW, EARY JF, GOOLEY TA et al.: A Phase I/II trial of iodine-131-tositumomab (anti-CD20), etoposide, cyclophosphamide, and autologous stem cell transplantation for relapsed B-cell lymphomas. Blood (2000) 96:2934–2942.
   PubMed Web of Science ®Google Scholar
• VOSE JM, BIERMAN PJ, ENKE C et al.: Phase I trial of Iodine-131 tositumomab with high-dose chemotherapy and autologous stem-cell transplantation for relapsed non-Hodgkin's lymphoma. J. Clin. Oncol (2005) 23:461–467.
   PubMed Web of Science ®Google Scholar
• WINTER JN, INWARDS DJ, SPIES S et al.: "Y Ibritumomab tiuxetan (Zevalin®; 90YZ) doses higher than.4mCi/kg may be safely combined with high-dose beam and autotransplant: the role for dosimetry [abstract]. Blood (2004) 104:116a.
   Google Scholar
• KRISHNAN AY, NADEMANEE A, FORMAN SJ et al.: The outcome of ZBEAIVI, a regimen combining 90Y ibritumomab tiuxetan with high dose chemotherapy in elderly patients with non-Hodgkin's lymphoma (NHL) [abstract]. J. Clin. Oncol (2005) 23:576a.
   PubMed Web of Science ®Google Scholar
• BYRD JC, MURPHY T, HOWARD RS et al.: Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J. Clin. Oncol (2001) 19:2153–2164.
   PubMed Web of Science ®Google Scholar
• O'BRIEN SM, KANTARJIAN H, THOMAS DA et al.: Rituximab dose-escalation trial in chronic lymphocytic leukemia. J. Clin. Oncol (2001) 19:2165–2170.
   PubMed Web of Science ®Google Scholar
• RUBINGER M, PENNER D: Decreasing incidence of infusion reactions with rituximab® administration by pre-medication with dexamethasone [abstract]. Blood (2001) 98:2476.
   Google Scholar
• BYRD JC, KITADA S, FLINN IW et al.: The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidene of caspase activation and apoptosis induction. Blood (2002) 99:1038–1043.
   PubMed Web of Science ®Google Scholar
• ALAS S, BONAVIDA B: Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/ paracrine loop and results in down-regulation of Bc1-2 and sensitization to cytotoxic drugs. Cancer Res. (2001) 61:5137–5144.
   PubMed Web of Science ®Google Scholar
• DIGAETANO N, MAO Y, ERBA E et ell.: Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br. J. Haematol (2001) 114:800–809.
   Google Scholar
• O'BRIEN S, KANTARJIAN H, BERAN M et al.: Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood (1993) 82:1695–1700.
   Google Scholar
• KEATING MJ, O& BRIEN S, KANTARJIAN H et al.: Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent. Blood (1993) 81:2878–2884.
   Google Scholar
• ALAS S, EMMANOUILIDES C, BONAVIDA B: Inhibition of interleukin 10 by rituximab results in down-regulation of bc1-2 and sensitization of B-cell non-Hodgkin's lymphoma to apoptosis. Clin. Cancer Res. (2001) 7:709–723.
   PubMed Web of Science ®Google Scholar
• SCHULZ H, KLEIN SK, REHWALD U et al.: Phase II study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia. Blood (2002) 100:3115–3120.
   PubMed Web of Science ®Google Scholar
• BYRD J, RAT K, PETERSON B et al.: Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood (2005) 105:49–53.
   PubMed Web of Science ®Google Scholar
• RAI KR, PETERSON BL, APPELBAUM FR: Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl. J. Med. (2000) 343:1750–1757.
   PubMed Web of Science ®Google Scholar
• BYRD JC, PETERSON BL, MORRISON VA: Randomized Phase II study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood (2003) 101:6–14.
   PubMed Web of Science ®Google Scholar
• WIERDA W, O& BRIEN S, WEN S et al.: Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J. Clin. Oncol (2005) 23:4070–4078.
   Google Scholar
• KEATING MJ, O& BRIEN S, ALBITAR M et al.: Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J. Clin. Oncol (2005) 23:4079–4088.
   Google Scholar
• KAY NE, GEYER SM, LIN T et al.: Combination chemotherapy with pentostatin, cyclophosphamide and rituximab induces high rate of remissions including complete responses and achievement of minimal residual disease in previously untreated B-chronic lymphocytic leukemia [abstract]. Blood (2004) 104:100a.
   PubMed Web of Science ®Google Scholar
• DRAPKIN R, DIBELLA NJ, CUSSAY LC et al.: Phase II multicenter trial of pentostatin and rituximab in patients with previously treated or untreated chronic lymphocytic leukemia [abstract]. Blood (2002) 100:803a.
   Web of Science ®Google Scholar
• WEISS MA, LAIVIANNA N, KALAYCIO J et at.: Pentostatin and cyclophosphamide 1241 compared to pentostatin, cyclophosphamide and rituximab as salvage therapy for patients with chronic lymphocytic leukemia [abstract]. J. Clin. Oncol. (2004) 22:574s.
   Google Scholar
• DILLMAN RO, SCHREEDER MT, KENNEDY PS, GREEN RJ, DEPRIEST C: Pentostatin, cyclophosphamide, and rituximab (PCR) for chronic lymphocytic leukemia (CLL) [abstract] . Blood (2003) 102:3016.
   PubMedGoogle Scholar
• ROBAK T, SMOLEWSKI P, URBANSKA-RYS H et al.: Rituximab followed by cladribine in the treatment of heavily pretreated patients with indolent lymphoid malignancies. [abstract]. Blood (2003) 102:2976.
   PubMedGoogle Scholar
• GILLEECE MH, DEXTER TM: Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood (1993) 82:807–812.
   PubMed Web of Science ®Google Scholar
• DYER MJ, HALE G, MARCUS R, WALDMANN H: Remission induction in patients with lymphoid malignancies using unconjugated CAMPATH-1 monoclonal antibodies. Leuk. Lymphoma (1990) 2:179–193.
   PubMed Web of Science ®Google Scholar
• LUNDIN J, KIMBY E, BJORKHOLM M et al.: Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood (2002) 100:768–773.
   PubMed Web of Science ®Google Scholar
• OSTERBORG A, DYER MJ, BUNJES D et al.: Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J. Clin. Oncol. (1997) 15:1567–1574.
   Google Scholar
• KEATING MJ, FLINN I, JAIN V et al.: Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood (2002) 99:3554–3561.
   PubMed Web of Science ®Google Scholar
• RAI KR, FRETER CE, MERCIER RJ et al.: Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. j Clin. Oncol. (2002) 20:3891–3897.
   PubMed Web of Science ®Google Scholar
• OSTERBORG A, FASSAS AS, ANAGNOSTOPOULOS A et al.: Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. Br. J. Haematol. (1996) 93:151–153.
   PubMed Web of Science ®Google Scholar
• LOZANSKI G, HEEREMA N, FLINN I et al.: Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood (2004) 103:3278–3281.
   PubMed Web of Science ®Google Scholar
• KENNEDY B, RAWSTRON A. CARTER C et al.: Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood (2002) 99:2245–2247.
   Google Scholar
• O'BRIEN S, KANTARJIAN H, THOMAS D et al.: Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer (2003) 98:2657–2663.
   Google Scholar
• MORETON P, KENNEDY B, LUCAS G et al.: Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. Clin. Oncol. (2005) 23:2971–2979.
   Web of Science ®Google Scholar
• WIERDA W, FADERL S, O'BRIEN S et al.: Combined cyclophosphamide, fludarabine, alemtuzumab, and rituximab (CFAR) is active for relapsed and refractory patients [abstract]. Blood (2004) 104:101a.
   Google Scholar
• FERRAJOLI A, O'BRIEN SM, CORTES JE et al.: Phae II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer (2003) 98:773–778.
   Google Scholar
• BARTLETT NL, YOUNES A. CARABASI MA et al.: Phase I study of SGN-30, a chimeric monoclonal antibody (mA6), in patients with refractory or recurrent CD30 + hematologic malignancies [abstract]. Blood (2002):362a.
   Google Scholar
• BARTLETT NL, BERNSTEIN SH, LEONARD JP et al.: Safety, antitumor activity and pharmacokinetics of six weekly doses of SGN-30 (anti-CD30 monoclonal antibody) in patients with refractory or recurrent CD30+ hematologic malignancies [abstract]. Blood (2003) 102:362a.
   Google Scholar
• STEIN H, MASON DY, GERDES J: The expression of the Hodgkin's disease associated antigen Ki-1 in reactive and neoplastic lymphoid tissue: evidence that Reed-Sternberg cells and histiocytic malignancies are derived from activated lymphoid cells. Blood (1985) 66:848–858.
   PubMed Web of Science ®Google Scholar
• BORCHMANN P, TREML JF, HANSEN H et al.: The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphoma. Blood (2003) 102:3737–3742.
   PubMed Web of Science ®Google Scholar
• WAHL AF, KLUSSMAN K, THOMPSON JD et al.: The anti-CD30 monoclonal antibody SGN-30 promotes growth arrest and DNA fragmentation in vitro and affects antitumor activity in models of Hodgkin's disease. Cancer Res. (2002) 62:3736–3742.
   PubMed Web of Science ®Google Scholar
• ANSELL S, BYRD J, HORWITZ SM et al.: Phase I/II study of a fully human anti-CD30 monoclonal antibody (MDX-060) in Hodgkin's disease (HD) and anaplastic large cell lymphoma (ALCL). Blood (2003) 102:Abstract 632.
   Google Scholar
• LEMAISTRE CF, SALEH MN, KUZEL TM et al.: Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood (1998) 91:405.
   Google Scholar
• SALEH MN, LEMAISTRE CF, KUZEL TM et al.: Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides. J. Am. Acad. Dermatol. (1998) 39:63–73.
   PubMed Web of Science ®Google Scholar
• SCHEINBERG DA, TANIMOTO M, MCKENZIE S: Monoclonal antibody M195: A diagnostic marker for acute myelogenous leukemia. Leukemia (1989) 3:440–445.
   PubMed Web of Science ®Google Scholar
• TANIMOTO M, SCHEINBERG DA, CORDON-CARDO C: Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195. Leukemia (1989) 5:339–348.
   Google Scholar
• CARON PC, DUMON L, SCHEINBERG DA: Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia. Clin. Cancer Res. (1998) 6:1421–1428.
   Google Scholar
• CARON PC, JURCIC JG, SCOTT AM: A Phase IB trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: Specific targeting without immunogenicity. Blood (1994) 83: 1760-1768.
   Google Scholar
• HINMAN LM, HANMANN PR, WALLACE R: Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: A novel and potent family of antitumor antibiotics. Cancer Res (1993) 53:3336–3342.
   PubMed Web of Science ®Google Scholar
• ZEIN N, PONCIN M, NILAKANTAN R, ELLESTAD GA: Calicheamicin gamma II and DNA: molecular recognition process responsible for site-specificity. Science (1989) 244:697-699. Expert Op/n. Biol. Ther (2005) 5(9)
   Google Scholar
• KELL WJ, BURNETT AK, CHOPRA R et al.: A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia. Blood (2003) 102:4277–4283.
   PubMed Web of Science ®Google Scholar
• ESTEY EH, GILES FJ, BERAN M et al.: Experience with gemtuzumab ozogamycin ('rnylotarg') and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood (2002) 99:4222–4224.
   PubMed Web of Science ®Google Scholar
• JURCIC JG, DEBLASIO T, DUMONT L, YAO T, SCHEINBERG D: Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia. Clin. Cancer Res. (2000) 6:372–380.
   PubMed Web of Science ®Google Scholar
• PETTI MC, PINAZZI MB, DIVERIO D et al.: Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin (Mylotarem CMA-676). Br. J. Haematol. (2001) 115:63–65.
   PubMed Web of Science ®Google Scholar
• BURKE JM, CARON PC, PAPADOPOULOS EB et aL: Cytoreduction with iodine-131-anti-CD33 antibodies before bone marrow transplantation for advanced myeloid leukemias. Bone Marrow Transplant. (2003) 32:549–556.
   PubMed Web of Science ®Google Scholar
• APPELBAUM FR, MATTHEWS DC, EARY JF et al.: The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia. Transplantation (1992) 54:829–833.
   PubMed Web of Science ®Google Scholar
• MIEDERER M, MCDEVITT MR, SGOUROS G et al.: Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates. J. Nud Med. (2004) 45:129–137.
   Web of Science ®Google Scholar
• JURCIC JG, LARSON SM, SGOUROS G et al.: Targeted alpha particle immunotherapy for myeloid leukemia. Blood (2002) 15:1233–1239.
   Google Scholar
• MATTHEWS DC, APPELBAUM FR, EARY JF et al.: Phase I study of (131) I-anti-CD24 antibody plus cyclophosphamide and total body irradiation for advanced acute leukemia and myelodysplastic syndrome. Blood (1999) 15:1237–1247.
   Google Scholar
• MATTHEWS DC, APPELBAUM FR, EARY JF: 131I-anti-CD45 antibody plus busulfan/cyclophosphamide in matched related transplants for AML in first remission. Blood (1996) 18:142a. Affiliation
   Google Scholar